Beam Therapeuticsinc Stock Performance
| BEAM Stock | USD 22.74 0.73 3.11% |
The firm shows a Beta (market volatility) of 3.75, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Beam TherapeuticsInc will likely underperform. Beam TherapeuticsInc right now shows a risk of 5.86%. Please confirm Beam TherapeuticsInc sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to decide if Beam TherapeuticsInc will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Beam TherapeuticsInc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Beam TherapeuticsInc is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (2.98) | Five Day Return (5.68) | Year To Date Return (16.93) | Ten Year Return 21.44 | All Time Return 21.44 |
1 | Beam Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating | 02/27/2024 |
2 | Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject to Rule 16b-3 | 03/06/2024 |
3 | Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency | 03/26/2024 |
4 | Acquisition by Evans John M. of 77500 shares of Beam TherapeuticsInc subject to Rule 16b-3 | 03/28/2024 |
5 | Beam Therapeutics CFO sells shares worth over 174k | 04/03/2024 |
6 | Beam Therapeutics Is In A Good Position To Deliver On Growth Plans | 04/11/2024 |
| Begin Period Cash Flow | 232.8 M |
Beam |
Beam TherapeuticsInc Relative Risk vs. Return Landscape
If you would invest 2,492 in Beam TherapeuticsInc on January 25, 2024 and sell it today you would lose (218.00) from holding Beam TherapeuticsInc or give up 8.75% of portfolio value over 90 days. Beam TherapeuticsInc is currently generating 0.0139% in daily expected returns and assumes 5.858% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Beam, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Beam TherapeuticsInc Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Beam TherapeuticsInc's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Beam TherapeuticsInc, and traders can use it to determine the average amount a Beam TherapeuticsInc's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0024
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BEAM |
Estimated Market Risk
| 5.86 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Beam TherapeuticsInc is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Beam TherapeuticsInc by adding Beam TherapeuticsInc to a well-diversified portfolio.
Beam TherapeuticsInc Fundamentals Growth
Beam Stock prices reflect investors' perceptions of the future prospects and financial health of Beam TherapeuticsInc, and Beam TherapeuticsInc fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Beam Stock performance.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0788 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 831.1 M | ||||
| Shares Outstanding | 82.31 M | ||||
| Price To Earning | 37.48 X | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 5.61 X | ||||
| Revenue | 377.71 M | ||||
| Gross Profit | (250.67 M) | ||||
| EBITDA | (156.47 M) | ||||
| Net Income | (132.53 M) | ||||
| Cash And Equivalents | 1.09 B | ||||
| Cash Per Share | 15.90 X | ||||
| Total Debt | 173.17 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 4.64 X | ||||
| Book Value Per Share | 12.47 X | ||||
| Cash Flow From Operations | (149.19 M) | ||||
| Earnings Per Share | (1.72) X | ||||
| Market Capitalization | 1.93 B | ||||
| Total Asset | 1.46 B | ||||
| Retained Earnings | (1.19 B) | ||||
| Working Capital | 1.01 B | ||||
| Current Asset | 2.89 B | ||||
| Current Liabilities | 706.6 M | ||||
About Beam TherapeuticsInc Performance
To evaluate Beam TherapeuticsInc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Beam TherapeuticsInc generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Beam Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Beam TherapeuticsInc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Beam's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -12.1 K | -12.7 K | |
| Return On Tangible Assets | (0.09) | (0.1) | |
| Return On Capital Employed | (0.14) | (0.13) | |
| Return On Assets | (0.09) | (0.1) | |
| Return On Equity | (0.14) | (0.14) |
Things to note about Beam TherapeuticsInc performance evaluation
Checking the ongoing alerts about Beam TherapeuticsInc for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Beam TherapeuticsInc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Beam TherapeuticsInc had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 377.71 M. Net Loss for the year was (132.53 M) with loss before overhead, payroll, taxes, and interest of (250.67 M). | |
| Beam TherapeuticsInc currently holds about 1.09 B in cash with (149.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Over 87.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Acquisition by Walsh Kathleen E of 16532 shares of Beam TherapeuticsInc at 34.33 subject to Rule 16b-3 |
- Analyzing Beam TherapeuticsInc's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Beam TherapeuticsInc's stock is overvalued or undervalued compared to its peers.
- Examining Beam TherapeuticsInc's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Beam TherapeuticsInc's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Beam TherapeuticsInc's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Beam TherapeuticsInc's stock. These opinions can provide insight into Beam TherapeuticsInc's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam TherapeuticsInc guide.Note that the Beam TherapeuticsInc information on this page should be used as a complementary analysis to other Beam TherapeuticsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Beam Stock analysis
When running Beam TherapeuticsInc's price analysis, check to measure Beam TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Beam TherapeuticsInc is operating at the current time. Most of Beam TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Beam TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Beam TherapeuticsInc's price. Additionally, you may evaluate how the addition of Beam TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Beam TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam TherapeuticsInc. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.72) | Revenue Per Share 4.896 | Quarterly Revenue Growth 14.78 | Return On Assets (0.08) | Return On Equity (0.15) |
The market value of Beam TherapeuticsInc is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Beam TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam TherapeuticsInc's market value can be influenced by many factors that don't directly affect Beam TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.